Table 3 Clinical features of 61 patients with extracranial metastatic oligodendrogliomas
Cases | Rate | |
|---|---|---|
Gender | ||
Total | 61 | |
Male | 33 | 54.1% (33/61) |
Female | 17 | 27.9% (16/61) |
Not given | 11 | 18.0% (11/61) |
Subjects | ||
Total | 61 | |
Asian | 10 | 16.4% (10/61) |
European | 30 | 49.2% (30/61) |
American & Canadian | 18 | 29.5% (18/61) |
Not given | 3 | 4.9% (3/61) |
Location of metastasis | ||
Total Sites | 110 | |
Bone/bone marrow | 47 | 42.7% (47/110) |
Lymph node | 22 | 20.0% (22/110) |
Liver | 7 | 6.4% (7/110) |
Scalp | 6 | 5.5% (6/ 110) |
Lung | 6 | 5.5% (6/ 110) |
Pleura | 4 | 3.6% (4/110) |
Chest wall | 3 | 2.7% (3/110) |
Iliopsoas muscle | 2 | 1.8% (2/110) |
Soft tissue | 2 | 1.8% (2/110) |
Parotid gland | 2 | 1.8% (2/110) |
Other | 9 | |
Adrenal | 1 | 0.9% (1/110) |
Spleen | 1 | 0.9% (1/109) |
Thoracic wall | 1 | 0.9% (1/110) |
Pancreas | 1 | 0.9% (1/110) |
Dorsal root ganglia | 1 | 0.9% (1/110) |
Abdomen | 1 | 0.9% (1/110) |
Spinal dura mater | 1 | 0.9% (1/110) |
Breast | 1 | 0.9% (1/110) |
Thymus gland | 1 | 0.9% (1/109) |